Controversy Debate 3: Neo-adjuvant/Adjuvant treatment in gastric cancer - The EU view
00:10:48

Controversy Debate 3: Neo-adjuvant/Adjuvant treatment in gastric cancer - The EU view

In this presentation from the ESMO 18th World Congress on Gastrointestinal Cancer, Dr. March Ychou provides the EU perspective on neo-adjuvant/adjuvant treatment in gastric cancer.

584 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Trending

The future of predicting outcomes for patients with MPNs: a patient knowledge bank
00:03:06

The future of predicting outcomes for patients with MPNs: a patient knowledge bank
198 Views
2 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Should stage lll colon cancer patients be treated with 3 months or 6 months of FOLFOX therapy?
00:03:14

Should stage lll colon cancer patients be treated with 3 months or 6 months of FOLFOX therapy?
339 Views
2 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
3 Myths About Breast Cancer
00:03:42

3 Myths About Breast Cancer
54 Views
6 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
iFCG yields unprecedented MRD negativity in CLL
00:02:41

iFCG yields unprecedented MRD negativity in CLL
64 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Case Based Panel Discussions - Metastatic Squamous NSCLC Low Tumor PD-L1 Frail Patient - Treatment
00:09:20

Case Based Panel Discussions - Metastatic Squamous NSCLC Low Tumor PD-L1 Frail Patient - Treatment
28 Views
6 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Thoughts On The Role Of Systemic Therapy In HCC
00:01:11

Thoughts On The Role Of Systemic Therapy In HCC
57 Views
10 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Debate on the use of MRD for multiple myeloma management
00:13:07

Debate on the use of MRD for multiple myeloma management
280 Views
2 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting 2016: The challenges Prof. Bruce Johnson will face as President-elect of Annual Meeting
00:00:57

Annual Meeting 2016: The challenges Prof. Bruce Johnson will face as President-elect of Annual Meeting
402 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
DFCI Wellness Study for CRC Patients
00:01:21

DFCI Wellness Study for CRC Patients
794 Views
2 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Identification of New BMP6 Pro-Peptide Mutations in Patients with Unexplained Iron-Overload
00:02:36

Identification of New BMP6 Pro-Peptide Mutations in Patients with Unexplained Iron-Overload
715 Views
2 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Interesting Data From ASH 2016 in Multiple Myeloma Therapies
00:01:00

Interesting Data From ASH 2016 in Multiple Myeloma Therapies
763 Views
2 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Spanish Lung Cancer Video Library - Combinaciones - immunoterapia con quimioterapia [720p]
00:03:11

Spanish Lung Cancer Video Library - Combinaciones - immunoterapia con quimioterapia [720p]
103 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Latest Videos

Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
2 Views
1 hour ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
0:02:44

New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
0 Views
1 hour ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3

Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
2 Views
1 hour ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
0:02:43

Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
0 Views
2 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
0:03:16

Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
0 Views
2 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
0:03:11

Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
1 Views
14 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Acute Lymphoblastic Leukemia

2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease

2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease
4 Views
3 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019

INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
6 Views
3 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase 1/2 AUGMENT-101 Trial @sloan_kettering
0:04:52

Phase 1/2 AUGMENT-101 Trial @sloan_kettering
13 Views
2 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Melanoma Rates Decline Found in Younger Population
0:03:21

Melanoma Rates Decline Found in Younger Population
2 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
12 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
EE:EE:EE

What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
38 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Acute Myelogenous Leukemia

Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
2 Views
3 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
5 Views
1 week ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
15 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
How to Manage MDS Patients who are Ineligible for Transplant
00:01:47

How to Manage MDS Patients who are Ineligible for Transplant
300 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The Recent Wave of Approval in AML
00:01:54

The Recent Wave of Approval in AML
138 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Updated Data on Gilteritinib in AML
00:01:12

Updated Data on Gilteritinib in AML
16 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Bladder Cancer

EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
0:02:13

EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
18 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
EV-103 Phase I Trial Presented at #ESMO19
0:01:45

EV-103 Phase I Trial Presented at #ESMO19
24 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
35 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer

Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
23 Views
3 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Strategies for Treating 2nd Line RCC Patients
00:01:17

Strategies for Treating 2nd Line RCC Patients
54 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Treating Newly Diagnosed RCC Patients
00:02:08

Treating Newly Diagnosed RCC Patients
53 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Bone Metastases

If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open is a Great Idea
00:00:40

If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open is a Great Idea
194 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Brain Cancer

Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
5 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Predicting Tumor Recurrence: How Does This Help Us?
0:03:05

Predicting Tumor Recurrence: How Does This Help Us?
7 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Predicting Tumor Recurrence
0:03:36

Predicting Tumor Recurrence
20 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
How does this affect clinicians today?
0:01:20

How does this affect clinicians today?
7 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
0:01:26

Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
15 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Oncoceutics Commemorates National Childhood Cancer Awareness Month

Oncoceutics Commemorates National Childhood Cancer Awareness Month
15 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Breast Cancer

Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3

Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
2 Views
1 hour ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial

CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
6 Views
1 week ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Is This Going To Affect Survival? @DukeCancer @DrLolaFayanju
0:03:14

Is This Going To Affect Survival? @DukeCancer @DrLolaFayanju
2 Views
1 week ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Radiation After Breast Cancer Diagnosis @DukeCancer @DrLolaFayanju
0:02:49

Radiation After Breast Cancer Diagnosis @DukeCancer @DrLolaFayanju
4 Views
1 week ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Who is Eligible for the AVIATOR Study? @SeattleCCA
0:02:08

Who is Eligible for the AVIATOR Study? @SeattleCCA
2 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The AVIATOR Study @SeattleCCA
0:04:33

The AVIATOR Study @SeattleCCA
3 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Business Management

Two Sided Payment Agreements & The Risks Involved
00:01:47

Two Sided Payment Agreements & The Risks Involved
116 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
MOASC COAnalyzer Tool Ricky Newton
01:01:00

MOASC COAnalyzer Tool Ricky Newton
99 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Cervical Cancer

Novel revelations in CLL biology with venetoclax/ibrutinib
00:02:24

Novel revelations in CLL biology with venetoclax/ibrutinib
93 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immunotherapy in gynecological cancers: current and future landscape
00:02:35

Immunotherapy in gynecological cancers: current and future landscape
474 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Chronic Lymphocytic Leukemia

Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
0:02:43

Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
0 Views
2 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
0:03:16

Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
0 Views
2 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
0:02:12

4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4 Views
23 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
SWAY Study @LevineCancer #ASH19
0:08:38

SWAY Study @LevineCancer #ASH19
0 Views
1 day ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
0:01:44

Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
0 Views
1 day ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
0:04:04

Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
0 Views
1 day ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Chronic Myelogenous Leukemia

Brentuximab Vedotin with Chemotherapy #ASH19
0:02:40

Brentuximab Vedotin with Chemotherapy #ASH19
0 Views
21 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
0:16:51

Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
7 Views
3 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Perspectives on the Future of CML
0:26:35

Perspectives on the Future of CML
10 Views
3 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Re-evaluating TKI in CML Patients During Pregnancy
0:15:04

Re-evaluating TKI in CML Patients During Pregnancy
3 Views
3 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CML and Pregnancy
0:15:30

CML and Pregnancy
4 Views
3 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Treating CML & Myelofibrosis Patients
00:01:34

Treating CML & Myelofibrosis Patients
319 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Colorectal Cancer

Are These Gene Fusions Targetable? @katherineclift4 @WUSTL
0:02:35

Are These Gene Fusions Targetable? @katherineclift4 @WUSTL
3 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Anti-EGFR Resistance Mechanism Using Tumor DNA Assay @katherineclift4 @WUSTL
0:07:15

Anti-EGFR Resistance Mechanism Using Tumor DNA Assay @katherineclift4 @WUSTL
24 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
BEACON Trial: What's Next?
0:02:57

BEACON Trial: What's Next?
11 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase 3 BEACON CRC Trial
0:04:43

Phase 3 BEACON CRC Trial
70 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic ...

Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic ...
31 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login